PART IV: FINLAND
Market Overview

Finland's biologics ecosystem encompasses 124+ biotechnology companies employing approximately 2,800 people, projected to grow at 9.4% CAGR (2022-2030). Key hubs include Helsinki/Espoo, Turku (strongest in biopharmaceuticals/diagnostics - 20 of 21 Finnish-developed drugs came from Turku companies), Kuopio (gene therapy center of excellence with FinVector's 500 employees), Oulu, and Tampere.

Section A: Finnish Therapeutic Developers
Major Companies

ORION CORPORATION / ORION PHARMA (Espoo)

Status: Public (Nasdaq Helsinki) | Employees: ~3,700 | Revenue: €1.54B (2024) | Market Cap: ~$10.1B

Finland's largest pharmaceutical company. R&D focus: oncology and pain. ODM-212 Phase 2 TEADES trial-initiated January 2026 for mesothelioma. New Cambridge UK Biologics R&D Centre opened 2025. October 2025 exclusive license with Abzena for antibody technology. €100M EIB loan, €10M Business Finland AI grant.

Clinical-Stage Companies
Company
Location
Focus
Key Data
Faron Pharmaceuticals
Turku
Bexmarilimab anti-Clever-1 for AML/MDS
63% ORR in HR-MDS, 76% in treatment-naïve; FDA Orphan Drug
Herantis Pharma
Espoo
HER-096 peptidomimetic for Parkinson's
Phase 1b ongoing, €5.2M raised Feb 2025
Aurealis Therapeutics
Kuopio
AUP-16 4-in-1 gene therapy for DFU
3x wound closure rate in Phase 2
TILT Biotherapeutics
Helsinki
TILT-123 oncolytic adenovirus with TNF-α/IL-2
$25M Series B May 2025
Valo Therapeutics
Helsinki
PeptiCRAd oncolytic virus + peptides
€19M raised March 2025
Nanoform
Helsinki
CESS nanoparticle formulations
Nanoenzalutamide superior bioavailability
Desentum
Espoo
DM-101PX recombinant hypoallergen vaccine
Phase 1 completed April 2025, Phase 2 planned
DelSiTech
Turku
Silica Matrix controlled release
$9M upfront + $200M+ milestone deal
Aplagon
Helsinki
APAC for thromboinflammatory diseases
Phase 2a, €7M raised Jan 2025
Early-Stage Companies
Company
Location
Focus
StemSight
Tampere
iPSC limbal stem cells for corneal blindness, €2.3M seed
Rappta Therapeutics
Helsinki
PP2A-reactivating molecular glues for cancer
RNatives
Kuopio
RNA-based gene regulation
Rokote Laboratories
Kuopio
Gene transfer vaccines
Polku Therapeutics
Helsinki
Neurodegenerative small molecules
Section B: Finnish Vendors & Service Providers
CDMOs

3PBIOVIAN (Turku)

Status: Private (Keensight Capital) | Employees: ~300 | Website: 3pbiovian.com

Global biologics CDMO formed February 2024 from merger of Biovian + 3P Biopharmaceuticals. End-to-end development: microbial, mammalian, viral vectors, cell therapy, pDNA. EMA certified, FDA inspected. 400+ GMP clinical batches. €50M+ Turku facility expansion (6,400 sqm) completed 2024-2025, 100 new jobs.

FINVECTOR (Kuopio)

Status: Ferring Ventures subsidiary | Employees: ~500 | Website: finvector.com

World leader in viral gene therapy manufacturing. New Finport 25,000 sqm state-of-the-art facility opened October 2024 - one of world's largest viral vector capacities. EMA authorised for clinical/commercial supply. Close ties to Prof. Seppo Ylä-Herttuala's pioneering gene therapy research.

CROs
Company
Location
Specialisation
Admescope/Symeres
Oulu
ADME-Tox, AAALAC accredited
Charles River
Kuopio
Research animal models
Experimentica
Kuopio
Ophthalmic/ocular models specialist
MedFiles
Kuopio
Full-service pharma/biotech/medtech
Pharmatest Services
Turku
Oncology + bone biology (unique combination), GLP
Saparo Translational
Kuopio
Preclinical translational
Diagnostics
Company
Location
Products
Abacus Diagnostica
Turku
GenomEra CDX automated DNA testing
ArcDia International
Turku
mariPOC® rapid antigen system, 9 respiratory pathogens
HyTest Ltd
Turku
Global leader in IVD monoclonal antibodies, cardiac markers
Blueprint Genetics
Espoo
Comprehensive genetic testing
Genomill Health
Turku
NGS liquid biopsies for cancer
Medix Biochemica
Espoo
mAbs and antigens for diagnostics
Research Infrastructure
  • Turku Bioscience Centre: Advanced core facilities (bioimaging, genomics, flow cytometry)
  • Kuopio Center for Gene and Cell Therapy (KCT): Academic-corporate interface, access to FinVector GMP
  • Terkko Health Hub: Largest Nordic health/life science startup hub (60+ startups, €hundreds of millions raised)
Key Investors
  • Business Finland: Government innovation funding
  • Tesi (Finnish Industry Investment): €151M invested 2022
  • Voima Ventures, Innovestor, Lifeline Ventures: Leading VCs
  • NordicNinja VC: Finnish-Japanese JV (Panasonic, Honda, Omron)